Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Clinical trial NCT02374099 · TERMINATED
Trial details
- NCT number
- NCT02374099
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-13
- Primary completion
- 2016-12-13
- Enrollment
- 97
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.